All In Biotech

NDA 204485 · Ph Health

Vasostrict

Vasopressin · Intravenous

Last checked: Nov 20, 2026Latest source record: Apr 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Apr 17, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

331

81 Phase 3, 37 recruiting

FAERS reports

4,443

4,277 serious, 1,737 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 21, 2026.

Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )

Mechanism: Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 2014 Original approval · Type 7 - Drug Already Marketed without Approved NDA LetterLabelReview
6 products under this application
  • VASOSTRICT · VASOPRESSIN 50UNITS/50ML (1UNITS/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • VASOSTRICT · VASOPRESSIN 60UNITS/100ML (0.6UNITS/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • VASOSTRICT · VASOPRESSIN 200UNITS/10ML (20UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • VASOSTRICT · VASOPRESSIN 20UNITS/100ML (0.2UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • VASOSTRICT · VASOPRESSIN 40UNITS/100ML (0.4UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • VASOSTRICT · VASOPRESSIN 20UNITS/ML (20UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Vasopressin" as an intervention, any sponsor and status, largest first.

All 331 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,360
  • off label use560
  • hypotension517
  • cardiogenic shock428
  • multiple organ dysfunction syndrome424
  • sepsis415
  • condition aggravated405
  • toxicity to various agents343
  • acute kidney injury342
  • vomiting320
  • stress319
  • abdominal pain301

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200517
200628
200732
200826
200943
201042
2011134
201271
201336
201488
201576
2016100
2017145
2018171
2019183
2020394
2021624
2022420
2023538
2024449
2025514
2026298

Recalls

1 FDA enforcement reports for this application.

  • Jan 11, 2024 · Class II · Ongoing

    Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,660 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.